IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expected to Post Earnings of -$0.41 Per Share

Equities research analysts predict that IDEAYA Biosciences, Inc. (NASDAQ:IDYAGet Rating) will report earnings of ($0.41) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for IDEAYA Biosciences’ earnings. The lowest EPS estimate is ($0.59) and the highest is ($0.17). IDEAYA Biosciences reported earnings of ($0.28) per share in the same quarter last year, which would indicate a negative year over year growth rate of 46.4%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.87) to ($0.86). For the next year, analysts anticipate that the business will post earnings of ($2.29) per share, with EPS estimates ranging from ($2.94) to ($1.64). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYAGet Rating) last released its earnings results on Tuesday, March 15th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.16). IDEAYA Biosciences had a negative net margin of 178.09% and a negative return on equity of 18.22%. The firm had revenue of $2.96 million during the quarter, compared to analyst estimates of $10.13 million. During the same period last year, the business posted ($0.18) earnings per share.

A number of brokerages have recently commented on IDYA. Zacks Investment Research upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Friday, March 18th. Stifel Nicolaus upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating and cut their price target for the company from $27.00 to $20.00 in a report on Thursday, March 10th. Finally, Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, March 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $29.40.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its position in IDEAYA Biosciences by 4.1% during the third quarter. The Manufacturers Life Insurance Company now owns 17,114 shares of the company’s stock worth $436,000 after buying an additional 681 shares during the last quarter. Redmond Asset Management LLC grew its position in shares of IDEAYA Biosciences by 5.8% in the fourth quarter. Redmond Asset Management LLC now owns 12,655 shares of the company’s stock valued at $299,000 after purchasing an additional 689 shares during the last quarter. Deutsche Bank AG grew its position in shares of IDEAYA Biosciences by 5.6% in the fourth quarter. Deutsche Bank AG now owns 19,907 shares of the company’s stock valued at $471,000 after purchasing an additional 1,063 shares during the last quarter. Barclays PLC grew its position in shares of IDEAYA Biosciences by 12.8% in the third quarter. Barclays PLC now owns 13,587 shares of the company’s stock valued at $347,000 after purchasing an additional 1,540 shares during the last quarter. Finally, Royal Bank of Canada grew its position in shares of IDEAYA Biosciences by 82.7% in the third quarter. Royal Bank of Canada now owns 3,524 shares of the company’s stock valued at $90,000 after purchasing an additional 1,595 shares during the last quarter. 83.69% of the stock is currently owned by hedge funds and other institutional investors.

IDYA stock opened at $10.69 on Friday. The business’s 50-day moving average price is $12.15 and its two-hundred day moving average price is $18.07. The firm has a market cap of $412.92 million, a PE ratio of -7.69 and a beta of 1.80. IDEAYA Biosciences has a 1-year low of $10.10 and a 1-year high of $28.00.

About IDEAYA Biosciences (Get Rating)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

Featured Stories

Get a free copy of the Zacks research report on IDEAYA Biosciences (IDYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.